<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>27792701</identifier>
<setSpec>0016-3813</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Ortiz-Zepeda, Maricela</dc:author>
<dc:author>López-Hernández, Manuel Antonio</dc:author>
<dc:author>Guajardo-Leal, Martha Lilia</dc:author>
<dc:author>Alvarado-Ibarra, Martha</dc:author>
<dc:author>Álvarez-Veral, José Luis</dc:author>
<dc:author>Cota-Range, Xochitl</dc:author>
<dc:description xml:lang="en">INTRODUCTION The prognosis, in the long term, of adolescents and young adults with acute de novo lymphoblastic leukemia, treated with a pediatric type protocol. OBJECTIVE To analyze the efficacy and tolerability of a chemotherapy regimen of pediatric type on patients 15-35 years old with de novo acute lymphoblastic leukemia, Ph(-). METHODS A retrospective study of patients received from 2001 to 2013, without initial infiltration of the central nervous system. They received the regimen called LALÍN. Terminal goals: frequency of initial remission, probability of survival free of leukemia and event-free survival for five years. RESULTS We included 101 patients; there were 29 relapses and 19 deaths. There was initial remission in 97% of the cases; survival free of leukemia of 0.58 and event-free survival 0.44. No difference in patients aged 16-21 years vs. 22-35 (p &gt; 0.55). Negative prognostic factors: abnormal karyotypes, except hyperdiploids (p = 0.001); &gt; 5% of blasts, on 14 day induction (p = 0. 0001); delay in the punctuality of the courses of the chemotherapy regimen (p = 0.0001). CONCLUSION A pediatric type regimen is applicable to patients aged from 16 to 35 years with acute lymphoblastic leukemia, without greater toxicity and a best survival free of leukemia. The count of &gt; 5% of blasts and the delay in the execution of the stages of the chemotherapy regimen are the stronger negative prognostic factors.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:date>2016 Sep - Oct </dc:date>
<dc:title xml:lang="es">Destino a largo plazo de adolescentes y adultos jóvenes con leucemia aguda linfoblástica (LAL) de novo tratados con un protocolo de tipo pediátrico.</dc:title>
<dc:title xml:lang="en">[Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type].</dc:title>
<dc:publisher>Gaceta medica de Mexico</dc:publisher>
</metadata>
</record>
</pubmed-document>
